| scholarly article | Q13442814 |
| P356 | DOI | 10.1136/BMJ.4.5730.271 |
| P953 | full work available at URL | https://europepmc.org/articles/PMC1819816 |
| https://europepmc.org/articles/PMC1819816?pdf=render | ||
| https://syndication.highwire.org/content/doi/10.1136/bmj.4.5730.271 | ||
| P932 | PMC publication ID | 1819816 |
| P698 | PubMed publication ID | 5475846 |
| P2093 | author name string | J. M. Sutherland | |
| M. J. Eadie | |||
| J. H. Tyrer | |||
| W. D. Hooper | |||
| P2860 | cites work | "Dilantin" overdose | Q44394817 |
| "Dilantin" overdosage | Q72110722 | ||
| Spectrophotometric determination of diphenylhydantoin | Q72927823 | ||
| P433 | issue | 5730 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | engineering | Q11023 |
| disease outbreak | Q3241045 | ||
| P304 | page(s) | 271-273 | |
| P577 | publication date | 1970-10-01 | |
| 1970-10-31 | |||
| P1433 | published in | The BMJ | Q546003 |
| P1476 | title | Outbreak of anticonvulsant intoxication in an Australian city | |
| Outbreak of Anticonvulsant Intoxication in an Australian City | |||
| P478 | volume | 4 |
| Q89934259 | A career in epilepsy |
| Q34450183 | A comparison of the bioavailability of two brands of phenytoin |
| Q40142216 | Anticonvulsant drugs. An update |
| Q70401102 | Anticonvulsant hypocalcaemia |
| Q44807459 | Association between antiepileptic drug switching and epilepsy-related events |
| Q36966092 | Bioavailability and dissolution of proprietary and generic formulations of phenytoin |
| Q40962396 | Bioavailability of Four Different Pharmaceutical Preparations of Carbamazepine |
| Q34451580 | Bioavailability of different preparations of paracetamol |
| Q45132697 | Bioavailability of four brands of phenytoin tablets |
| Q67342679 | Bioavailability of phenytoin from various pharmaceutical preparations in children |
| Q44665404 | Bioavailability of three phenytoin preparations in healthy subjects and in epileptics |
| Q33636607 | Bioequivalence criteria for cyclosporine. |
| Q38310505 | Bioequivalence of 2 azithromycin capsule formulations: a randomized, single-dose, open-label, 2-period crossover study in healthy male pakistani volunteers |
| Q37514530 | Bioequivalence of antiepileptic drugs: how close is close enough? |
| Q72693526 | Bioinequivalence and drug toxicity. How great is the problem and what can be done? |
| Q69173257 | Blood phenytoin concentrations produced by ingestion of three different phenytoin preparations |
| Q43125497 | Changing lamotrigine preparations in epilepsy patients. Experiences of a university epilepsy outpatient centre |
| Q41175485 | Clinical Monitoring of Therapeutic Drugs |
| Q39806205 | Clinical Pharmacokinetics of Phenytoin |
| Q38682717 | Clinical features and management of poisoning due to phenytoin |
| Q69811428 | Clinical significance of generic inequivalence of three different pharmaceutical preparations of phenytoin |
| Q74417062 | Comparison of phenytoin serum concentrations in premature neonates following intravenous and oral administration |
| Q73079080 | Differences in reference products: dissolution and in vivo evidence |
| Q67265911 | Diphenylhydantoin Intoxication Mimicking Botulism |
| Q93756989 | Diphenylhydantoin intoxication in a group of military aviators: A case report |
| Q38756091 | Disposition of anticonvulsants in childhood |
| Q47868276 | Drug Permeation through Membranes III: Effect of pH and Various Substances on Permeation of Phenylbutazone through Everted Rat Intestine and Polydimethylsiloxane |
| Q41615135 | Drug management of hypertensive disorders of pregnancy |
| Q73120411 | Drug-excipient interactions and their affect on absorption |
| Q40006967 | Drugs, Drug Products and Prescribing Habits |
| Q34517810 | Effect of increased bioavailability of phenytoin tablets on serum phenytoin concentration in epileptic out-patients |
| Q33573439 | Elucidating raw material variability--importance of surface properties and functionality in pharmaceutical powders |
| Q34277361 | Excipients, adverse drug reactions and patients' rights. |
| Q70428736 | Factors involved in an outbreak of phenytoin intoxication |
| Q93727478 | Generic equivalence and non-equivalence of drugs |
| Q71456738 | Generic prescribing for epilepsy. Is it safe? |
| Q33838670 | Generic substitution for brand name antiepileptic drugs: a survey. |
| Q38011598 | Impact of excipient interactions on drug bioavailability from solid dosage forms |
| Q40884033 | Impact of generic substitution of anticonvulsants on the treatment of epilepsy |
| Q70733938 | Implications of intraindividual variability in bioavailability studies of furosemide |
| Q34045758 | Is generic prescribing acceptable in epilepsy? |
| Q34661823 | Issues in the formulation of drugs for oral use in children: role of excipients |
| Q68886650 | Laboratory control of anticonvulsant dosage |
| Q64114579 | Methods to Study Colon Release: State of the Art and An Outlook on New Strategies for Better Biorelevant Release Media |
| Q54766078 | One Daily Dose of Diphenylhydantoin for Patients with Epilepsy |
| Q39511528 | Pharmaceutical excipients. Adverse effects associated with 'inactive' ingredients in drug products (Part II). |
| Q44673846 | Pharmacokinetics of single and multiple doses of phenytoin in man |
| Q34063156 | Pharmacologic therapy of ventricular arrhythmias |
| Q36262610 | Phenytoin poisoning |
| Q35843529 | Prescribing antiepileptic drugs: should patients be switched on the basis of cost? |
| Q40081913 | Psychological Effects Caused by Drugs in Overdose |
| Q35171189 | Reformulation of injectable vitamin A: potential problems |
| Q34515325 | Serum concentrations and bioavailability of rifampicin and isoniazid in combination |
| Q70529941 | Serum folic acid and phenytoin levels in permanently hospitalized epileptic patients receiving anticonvulsant drug therapy |
| Q39945199 | Some aspects of the influence of formulation on the bioavailability of drugs from solid dosage forms |
| Q28319040 | Spasticity due to phenytoin toxicity |
| Q69576103 | The Bioavailability of Drug Products |
| Q39458379 | The bioavailability of phenytoin |
| Q53901254 | The pharmacokinetics of acetanilide and of diphenylhydantoin sodium. |
| Q70478042 | Therapeutic non-equivalence |
| Q36809784 | Trade names or approved names. Part III. Special cases. Clinical trials |
| Q41240036 | Trade names or approved names. Point II. Points of view. The clinical pharmacologist |
| Q70603624 | Variation in Biologic Availability of Digoxin from Four Preparations |
| Q69570339 | Vitamin D-dependent rickets in institutionalized, mentally retarded children receiving long-term anticonvulsant therapy. I. A survey of 288 patients |
| Q70443699 | Withdrawal of oxyphenisatin acetate, diacetoxydiphenolisatin and triacetyldiphenolisatin from the Australian market |
Search more.